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ABSTRACT: It has been well established that cigarette smoking is a powerful risk factor 
for coronary artery disease. A number of epidemiologic studies have shown a strong asso-
ciation between cigarette smoking and atherosclerosis, myocardial infarction and death from 
coronary artery disease. In addition to active smoking, passive smoking can also carry a risk 
of coronary artery disease. Although the detailed mechanism through which cigarette smok-
ing is associated with cardiovascular disease has not yet been clarified, it is suggested that 
cigarette smoking is related to thrombogenesis, as well as atherogenesis, and blood platelet 
behavior is thought to be prominent among the proposed mechanisms involved in athero-
genesis and thrombogenesis. The following is a review of evidence that cigarette smoking 
affects platelet function. 
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PLATELET ACTIVATION BY 
CIGARETTE SMOKING 
 
Platelet aggregation studies  
The most common approach to studying the ef-
fect of cigarette smoking on platelet function has been 
to measure the platelet aggregation response to agonists 
ex vivo, e.g. adenosine diphosphate (ADP), collagen, 
thrombin, platelet activating factor, etc. The rela-
tionship between platelet aggregation and cigarette 
smoking was examined by a large number of studies. 
These studies suggest that smoking has two effects on 
platelets, i.e., a significant acute potentiation of platelet 
activation occurring shortly after smoking a cigarette, 
and a chronic desensitization of the cell to activating 
agents occurring during the period between cigarettes. 
Although there are numerous longitudinal investiga-
tions of the acute effects of smoking on platelet aggre-
gation, the results produced have been conflicting. 
Some have demonstrated increased platelet aggregabil-
ity immediately after smoking [1-4] while others have 
found no such change [5-7]. Blache and colleagues [4] 
observed that platelet aggregation to thrombin and ADP 
increased significantly 10 minutes after inhalation of 
one cigarette smoke. However, Siess and colleagues [5] 
demonstrated that cigarette smoke inhalation did not 
enhance platelet aggregation stimulated by ADP, epi-
nephrine, and collagen. On the other hand, regarding 
the effects of chronic smoking, there have also been 
conflicting reports of increased, decreased and unal-
tered platelet aggregation response to agonists ex vivo 
by conventional platelet aggregometric methods [8-10]. 
The cross sectional results from the Caerphilly Collabo-
rative Heart Disease Study [11] show that the ADP-
induced platelet aggregation response was increased 
among habitual smokers, but the finding was mainly 
seen in the subjects who had smoked cigarettes shortly 
before venisection. 
Conversely, Foo and colleagues [9] demonstrated 
that in habitual smokers platelet aggregability to aggre-
gating agents was reduced, compared with non-
smokers. Lassila and colleagues [10] demonstrated that 
platelet aggregation responses to ADP and epinephrine 
at rest were similar in non-smokers and smokers but 
that after submaximul exercise the responses were less 
in the smokers than in the non-smokers. From these
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  Smokers Nonsmokers  P 
Spontaneous aggregation       
   Small aggregates (10
5 counts
 x10 second)  129±170  62±105  <0.0001 
Epinephrine 1 mm       
   Small aggregates (10
5 counts
 x10 second)  523±253  491±218   
   Medium aggregates  227±146  153±144  <0.0001 
   Large aggregates  202±201  135±184  0.0015 
Epinephrine 5 mm       
   Small aggregates (10
5 counts
 x10 second)  346±217  383±227   
   Medium aggregates  232±122  190±98  0.0318 
   Large aggregates  350±222  278±212  0.0466 
ADP 1 mm       
   Small aggregates (10
5 counts
 x10 second)  592±269  458±243  0.0005 
   Medium aggregates  169±180  108±148  0.0025 
   Large aggregates  139±201  91±184  0.0007 
ADP 5 mm       
   Small aggregates (10
5 counts
 x10 second)  236±123  247±140   
   Medium aggregates  154±58  156±65   
   Large aggregates  529±185  486±184   
      
results of reduced platelet aggregability in habitual 
smokers it has been suggested that in chronic smokers, 
increased generation of platelet agonists in vivo might 
result in platelet receptor down-regulation and thus, 
aggregation response to these agonists is depressed ex 
vivo. However, conventional platelet aggregation stud-
ies are inherently limited in the information they can 
provide concerning the effects of smoking on platelet 
aggregation in vivo. Recently, however, platelet aggre-
gability has been assessed by newly developed systems 
to closely evaluate platelet aggregation.   
A conventional aggregometor using optical den-
sity provides only information about large aggregates of 
platelets, because small aggregates may be formed 
when platelet-rich plasma is stirred at 37 degrees C in 
the absence of chemical stimulants [12]. In contrast, a 
particle-counting technique using laser light scattering 
makes it possible to separately detect small, medium 
and large aggregates. Fusegawa and colleagues [13] 
compared the differences in platelet aggregability be-
tween 90 healthy male smokers and 141 age-matched 
nonsmoking healthy males, using this technique.  In 
spontaneous aggregation, small aggregates were higher 
in smokers than in nonsmokers. Detection of medium 
and large aggregates formed by 1 or 5 µM of epineph-
rine and all aggregates by 1 µM of epinephrine were 
significantly higher in smokers than in nonsmokers. 
Aggregation induced by 5 µM of ADP showed no sig-
nificant difference in small, medium, and large aggre-
gates between the groups (Table 1). Smokers showed a 
positive correlation between age and 1 µM epinephrine-
induced large platelet aggregates (R=0.43, P<0.001) 
and 1 µM ADP-induced medium (R=0.30, P<0.01) and 
large aggregates (R=0.32, P<0.01). Smokers also 
showed a positive correlation between fibrinogen con-
centration in plasma and small spontaneous aggregates 
(R=0.37, P<0.001).  On the other hand, nonsmokers 
showed a significant positive correlation between age 
and small spontaneous aggregates (R=0.32, P<0.01), a 
positive correlation between fibrinogen and 1 (R=0.23, 
P<0.01) or 5µM (R=0.28, P<0.01) epinephrine-induced 
large aggregates, and between 1 µM ADP-induced 
large aggregates (R=0.24, P<0.01). These results sug-
gest that platelet aggregability evaluated by small ag-
gregates is enhanced in habitual smokers, and that long-
term smoking enhances the sensitivity of platelets to 
epinephrine or ADP.  
Measurement of platelet aggregability using 
conventional aggregometry requires making platelelet-
rich plasma, so results can be obtained about 60 
minutes after blood sampling. In contrast, a novel type 
platelet aggregometor, the WBA analyzer (SSR 
Engineering, Yokohama, Japan) is a system based on a 
screen filtration pressure (SFP) method, which 
measures the resistance of the flow of whole blood 
samples containing platelet aggregates through a micro-
mesh filter with 300 square openings of 20×20  µm. 
Since this system requires only 5 minutes to obtain 
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immediately after blood sampling, and this can be 
considered to reflect in vivo platelet function more 
closely. Using this system, platelets were stimulated by 
various concentrations of ADP. The filtration pressure 
raised by clogging of the filter by aggregatory clots was 
measured as an index of platelet aggregation. The 
percent aggregation rate was calculated in each ADP 
concentration by the maximum filtration pressure as 
100% aggregation. An ADP concentration producing 
50% aggregation was calculated as a platelet 
aggregatory threshold index (PATI) [25]. We measured 
the platelet aggregatory threshold index (PATI) 5 
minutes after blood sampling and compared it with that 
60 minutes after blood sampling in 20 healthy male 
volunteers (10 smokers and 10 non-smokers) [25]. In 
the non-smokers, PATI was 10.3±2.3 µM 5 minutes 
after blood sampling, decreasing to 4.7±1.5 (P<0.001) 
60 minutes after blood sampling. In the smokers, the 
PATI was 7.7±2.9 µM 5 minutes after blood sampling, 
decreasing to 3.8±1.5 (P<0.001) at 60 minutes after 
blood sampling (Figure 1). In the smokers, the PATI 5 
minutes after blood sampling increased after 4 weeks’ 
cessation of smoking (10.4±2.9, P<0.01), although the 
PATI 60 minutes after blood sampling did not change 
(4.2±1.6µM) (Figure 2). These results suggest that, in 
habitual smokers, platelet aggregability is enhanced 
immediately after blood sampling and platelets are 
constantly activated in-vivo.  
Other platelet function studies 
An alternative approach to the study of platelet 
function in vivo has been that of radiolabelled platelet 
turnover studies. A shorter platelet lifespan has been 
observed in chronic smokers [15,16]. While platelet 
turnover studies provide definitive evidence for platelet 
function abnormality in chronic smokers, they do not 
discriminate between the direct effect of smoking on 
platelets and altered platelet function caused by 
smoking-induced vascular damage. Although studies of 
platelet turnover provide the opportunity to study 
platelet kinetics in vivo, these studies have several 
intrinsic limitations; they provide conclusions that are 
highly model-dependent and do not lead themselves to 
repeated application within persons.  
Platelet specific proteins, platelet factor 4 (PF-4) 
and  β-thromboglobulin (β-TG), are released from 
platelet α-granules into circulating blood plasma when 
platelets are activated. Elevated plasma levels of PF-4 
[17] and β-TG [18] have been reported in the blood of 
chronic smokers, and the levels are also enhanced as an 
acute effect of smoking [4]. To investigate in-vivo 
platelet activation states, flow-cytometric analysis of 
the activation-dependent platelet membrane surface 
glycoproteins, including P-selectin [19-21] or 
activation-dependent neoepitope of glycoprotein (GP) 
IIb/IIIa [20,22], is available. P-selectin is a component 
of the α-granule membrane of resting platelets and is 
expressed on the platelet surface membrane after α-
granule secretion when platelets are activated [19]. A 
soluble isoform of P-selectin shedded from the platelet 
surface can be also measured in the blood plasma [23]. 
Figure 1. Time-dependent changes in PATI in non-
smokers (left) and smokers (right). In both subject
groups, PATI was decreased at 60 minutes after
blood sampling. The PATI values at 5 minutes after
blood sampling were significantly lower in the smok-
ers than in the non-smokers, while the values at 60
minutes were identical in both subject groups [25]. 
Figure 2. Effect of 4 weeks’ cessation of smoking on 
platelet aggregability. PATI at 5 minutes after blood 
sampling increased after cessation of smoking (left), 
although there was no change in the PATI at 60 
minutes after blood sampling (right).  
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platelets and a higher plasma soluble P-selectin level in 
chronic smokers than non-smokers was demonstrated 
and thus increased in-vivo platelet activation was 
confirmed [24]. A chronic effect of cigarette smoking 
on platelet activation has also been shown by a few 
studies measuring elevated excretion of a thromboxane 
A2 metabolite (TX-M) in urine by gas chromatography-
mass spectrometry [25,26]. FitzGerald and coworkers 
[27] demonstrated the platelet origin of TX-M by a 
platelet-selective low dose of acetylsalicylic acid 
(ASA), which blocks the cyclooxygenase enzyme. The 
increased smoking-induced excretion of TX-M could be 
masked with ASA for the survival time of platelets. 
Platelets have an L-arginine-nitric oxide (NO) pathway 
through constitutive NO synthase (NOS) in human 
platelets. Platelet aggregation is inhibited by L-arginin, 
a precursor of NO, and potentiated by NG-
monomethyl-L-arginine (L-NMMA), an inhibitor of 
NOS. Platelet aggregation is acompanied by an increase 
in the intracellular level of cyclic guanosine 3', 5'-
monophosphate (cGMP) [28]. These findings indicate 
evidence of the functional L-arginine-NO pathway in 
platelets during aggregation, which acts as a negative 
feedback mechanism to inhibit not only platelet 
activation [29], but also recruitment after aggregation 
[30]. Recently, it has been shown that impaired platelet-
derived NO (PDNO) production may contribute to the 
pathophysiology of acute coronary syndrome [31]. In 
chronic smokers, the bioactivity of PDNO is impaired, 
and it is considered that this impairment may be caused 
by an imbalance in the intraplatelet redox state through 
increased oxidative stress in smokers [32].  
Passive smoking and platelet activation 
“Passive smoking” or “environmental tobacco 
smoke (ETS)” is the term used to characterize tobacco 
combustion products inhaled by non-smokers in the 
proximity of burning tobacco. Most ETS exposure is 
from sidestream smoke emitted from the burning tip of 
the cigarette. Non-smokers chronically exposed to ETS 
are believed to assume health risks similar to those of a 
light smoker. Several epidemiological studies have 
shown that the risk of ischemic heart disease is about 
30% greater in non-smokers who live with smokers 
than in those who do not [33-35]. Although 
environmental exposure to cigarette smoking is only 
about 1% that of smoking, the risk is nearly half of the 
active smoker [36].  
An earlier study demonstrated that the rela-
tionship between passive smoking and the higher risk 
of hemostatic imbalance [37]. Acute exposure to 
passive smoke induced in non-smokers a short-lasting 
activation of platelet function and the prostaglandin 
system, followed by a quick recovery after only 15 
minutes’ exposure to passive cigarette smoke. Six hours 
after exposure no changes were detected. Repeated 
exposure of non-smokers to passive smoke, however, 
resulted in a continuous change in the basal values for 
platelet aggregation, while circulating endothelial cells 
and microaggregates were similar but less severe. 
Platelet proteins were less altered. Changes were 
comparable to those seen in smokers, characterized by 
an activation of platelet function, namely, a decrease in 
platelet sensitivity and binding sites to the antiaggre-
gatory prostagrandin (PG) I2.  
In one experiment, non-smokers and smokers 
were asked to smoke two cigarettes [38]. The smokers’ 
platelets, which were less sensitive to exogenous PGI2 
than the non-smokers’ platelets at the beginning of the 
experiment, did not significantly change their activity in 
response to the two cigarettes. Most likely, the smokers’ 
platelets were already desensitized to antiaggregatory 
PGI2 because of chronic exposure to the toxins in 
cigarette smoke, so the addition of a relatively small 
(compared with what a smoker receives continuously) 
amount of toxins in two cigarettes had no additional 
effects. In contrast, smoking just two cigarettes 
significantly decreased non-smokers’ platelet sensitivity 
to PGI2, to the point that it was not significantly 
different from that of habitual smokers. These data 
demonstrate that the responses of non-smokers and 
smokers to toxins in the cigarette smoke are often very 
different. 
In another experiment that more closely parallels 
the experience of non-smokers [38], platelet sensitivity 
to PGI2 was measured in smokers and non-smokers 
before and after they sat in a room for 20 minutes 
where cigarettes had been smoked just before the 
experimental subjects entered. Again, there was no 
significant change in the sensitivity to PGI2 among the 
smokers, but a significant decrease in the sensitivity to 
PGI2 among the non-smokers, to the point that their 
platelet sensitivity to PGI2 was not discernibly different 
from that of the smokers. These data indicate that non-
smokers are much more sensitive to tobacco smoke 
exposure than smokers, and that very low levels of ETS 
exposure can have a major impact on non-smokers’ 
platelet activity. Actually, Davis and colleagues [39-43] 
observed a decrease in the platelet aggregation ratio 
(0.87 to 0.78; P=0.002), which reflects an increased 
formation of platelet aggregates, and found that passive 
smoking increased platelet platelet aggregation with a 
30     Inoue T magnitude similar to that observed in active smoking. 
It also appears that the process saturates at low 
doses; once the non-smoker has been exposed to even a 
low dose of ETS, the platelets are maximally activated, 
similar to a habitual smoker. These data also indicate 
that dose-based extrapolations from smokers to non-
smokers using “cigarette equivalents” will grossly 
underestimate the risks to non-smokers of breathing 
second-hand smoke.    
Animal data also support this conclusion. In 
studies done to evaluate the effects of ETS on heart 
disease, it has been found that bleeding time, another 
measure of platelet activity, is significantly shortened in 
both rabbits [44,45], and rats [46] exposed to low doses 
of ETS, with no additional effects at higher doses. 
These findings indicate activated platelet function after 
ETS exposure. Apparently, the acute response is more 
pronounced in non-smokers than in smokers. On 
repeated exposure to cigarette smoke, platelet function 
in non-smokers approaches that of smokers.  
 
CONCLUSION 
Cigarette smoking is a major risk factor for 
cardiovascular morbidity and mortality and is a leading 
cause of death. The effect of cigarette smoking on 
coronary risk factors is pervasive. Unfavorable effects 
include enhancement of platelet function.  Platelet 
activation by cigarette smoking is linked to thrombosis 
formation, including onset of myocardial infarction. In 
light of the adverse effects on platelet function, 
cessation of smoking should be encouraged. 
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